Inspire Trust Co. N.A. Buys Shares of 22,000 Novo Nordisk A/S (NYSE:NVO)

Inspire Trust Co. N.A. purchased a new position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 22,000 shares of the company's stock, valued at approximately $1,892,000.

Other institutional investors have also recently made changes to their positions in the company. Victory Capital Management Inc. raised its position in Novo Nordisk A/S by 58.5% in the fourth quarter. Victory Capital Management Inc. now owns 62,897 shares of the company's stock valued at $5,410,000 after purchasing an additional 23,223 shares during the period. Bryn Mawr Capital Management LLC raised its holdings in Novo Nordisk A/S by 358.8% in the 4th quarter. Bryn Mawr Capital Management LLC now owns 38,898 shares of the company's stock valued at $3,346,000 after buying an additional 30,420 shares during the period. Clear Creek Financial Management LLC acquired a new position in Novo Nordisk A/S in the fourth quarter valued at about $450,000. DSM Capital Partners LLC lifted its position in Novo Nordisk A/S by 16.7% in the fourth quarter. DSM Capital Partners LLC now owns 2,007,412 shares of the company's stock valued at $172,678,000 after buying an additional 286,912 shares during the last quarter. Finally, Patrick M Sweeney & Associates Inc. boosted its stake in Novo Nordisk A/S by 81.2% during the fourth quarter. Patrick M Sweeney & Associates Inc. now owns 11,155 shares of the company's stock worth $960,000 after buying an additional 5,000 shares during the period. Hedge funds and other institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S Stock Down 0.0%

Shares of NYSE:NVO opened at $68.19 on Thursday. Novo Nordisk A/S has a fifty-two week low of $57.00 and a fifty-two week high of $148.15. The firm's 50 day moving average price is $66.82 and its 200 day moving average price is $83.65. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62. The stock has a market cap of $306.02 billion, a price-to-earnings ratio of 20.73, a price-to-earnings-growth ratio of 0.90 and a beta of 0.65.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported $0.92 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.92. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. The business had revenue of $11.87 billion during the quarter. As a group, equities research analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on NVO shares. StockNews.com upgraded shares of Novo Nordisk A/S from a "buy" rating to a "strong-buy" rating in a report on Friday, April 25th. Guggenheim cut Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research note on Thursday, April 17th. Dbs Bank cut Novo Nordisk A/S to a "sell" rating in a research note on Friday, April 25th. BNP Paribas began coverage on Novo Nordisk A/S in a research note on Tuesday, April 15th. They set an "underperform" rating on the stock. Finally, Stifel Nicolaus cut Novo Nordisk A/S from a "buy" rating to a "hold" rating in a report on Monday, March 3rd. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating, five have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $135.00.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.